Cabot Corporation $CBT Shares Purchased by Fiera Capital Corp

Fiera Capital Corp boosted its position in Cabot Corporation (NYSE:CBT) by 30.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 213,314 shares of the specialty chemicals company’s stock after purchasing an additional 49,181 shares during the period. Fiera Capital Corp’s holdings in Cabot were worth $14,138,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in CBT. NewEdge Advisors LLC lifted its position in Cabot by 2,559.5% in the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after purchasing an additional 947 shares during the period. Goldman Sachs Group Inc. lifted its position in Cabot by 32.5% in the first quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock valued at $36,802,000 after purchasing an additional 108,645 shares during the period. Empowered Funds LLC lifted its position in Cabot by 102.6% in the first quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after purchasing an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cabot by 3.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in Cabot by 409.0% in the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the period. Institutional investors and hedge funds own 93.18% of the company’s stock.

Cabot Price Performance

CBT stock opened at $82.88 on Tuesday. The firm has a 50 day moving average of $79.29 and a 200-day moving average of $73.25. Cabot Corporation has a 12-month low of $58.33 and a 12-month high of $89.46. The company has a current ratio of 1.45, a quick ratio of 0.96 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.28 billion, a price-to-earnings ratio of 15.67, a PEG ratio of 10.67 and a beta of 0.82.

Cabot (NYSE:CBT) last issued its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.14. Cabot had a return on equity of 21.33% and a net margin of 7.97%.The firm had revenue of $904.00 million during the quarter, compared to the consensus estimate of $900.31 million. During the same period in the previous year, the firm posted $1.90 EPS. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. As a group, equities analysts expect that Cabot Corporation will post 6.32 EPS for the current fiscal year.

Cabot Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 29th will be given a dividend of $0.4725 per share. The ex-dividend date is Friday, May 29th. This represents a $1.89 annualized dividend and a dividend yield of 2.3%. This is an increase from Cabot’s previous quarterly dividend of $0.45. Cabot’s payout ratio is presently 35.73%.

Analyst Ratings Changes

CBT has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Cabot from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Wednesday, May 13th. Mizuho raised their price objective on shares of Cabot from $75.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research report on Tuesday, May 26th. Truist Financial assumed coverage on shares of Cabot in a research report on Monday. They set a “buy” rating and a $98.00 price target for the company. Finally, Wall Street Zen downgraded shares of Cabot from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $83.80.

Cabot Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.